TP53 and ovarian carcinoma: HO-3867 showed more clinically relevant IC50 values as compared to APR-246, and synergistic effects were observed when combined with the PARP inhibitor olaparib in vitro and in vivo in a xenograft model of advanced ovarian cancer with mutant p53.